The study is an experimental pre-post-test design involving 10 patients with severe ED non-responsive to sildenafil. Safety parameters included pain, hematoma, local bleeding, and infection, while efficacy was measured using the IIEF-5 questionnaire, EHS, and morning erection.
Men aged 40-65 years who undergo treatment at the Andrology Clinic of RSUD Dr. Soetomo.
Severe erectile dysfunction caused by organic factors for at least 6 months, based on an IIEF-5 score of 5-7
History of undergoing treatment with sildenafil 100 mg for four sessions.
Evaluation of IIEF-5 score < 22 and not meeting the MCID criteria, defined as an IIEF-5 score increase of less than 4
Anatomical abnormalities of the penis that are clinically visible, such as Peyronie's disease, a history of priapism, a history of penile implants, skin irritation, and lesions in the area surrounding the penile skin.
Active and significant systemic or local infection.
History of bleeding or blood clotting disorder therapy.
History of systemic autoimmune disorders and immunosuppressive treatment